Compare Quest Diagnostics Inc (DGX) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Ralph Lauren Corp — how do they compare? Quest Diagnostics Inc trades at $203.55 (market cap $22.80B), while Ralph Lauren Corp trades at $376.1 (market cap $21.96B). The key difference: Quest Diagnostics Inc and Ralph Lauren Corp are close in size by market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | RL | |
|---|---|---|
Market Cap | $22.80B | $21.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $414.25 |
52-Week Low | $166.42 | $283.34 |
Enterprise Value | $28.82B | $22.90B |
Dividend Yield | 1.67% | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Ralph Lauren (RL) trades at $374.49, down 5.17% on the day, showing bearish technical momentum despite strong fundamentals. The company demonstrates robust financial performance with consistent earnings beats, including Q1 2026 EPS of $2.80 beating expectations of $2.55. Revenue growth accelerated to $7.08 billion in 2025 with net income margin expanding to 10.49%. Analyst consensus remains strongly bullish with 66% buy ratings and a $446.25 price target representing 19% upside potential.
The stock presents a compelling growth opportunity with strong brand momentum and digital expansion driving performance, though premium valuation metrics and technical bearish signals warrant caution. Key risks include macroeconomic sensitivity and competitive pressures in the apparel sector, while institutional sentiment remains positive given the company's execution on its Next Great Chapter strategy and Asia growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
